RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a biopharmaceutical company founded in 2010 and headquartered in Novato, California. The company went public in January 2014 and has established itself as a leader in developing treatments for rare and ultra-rare genetic diseases. Ultragenyx focuses on identifying, acquiring, developing, and commercializing novel therapeutic products that address significant unmet medical needs in patient populations that often have no approved treatment options. The company operates globally across North America, Europe, Latin America, and other international markets, with a particular emphasis on both biological therapies and cutting-edge gene therapies.